



## ASX ANNOUNCEMENT

### **Lumos Receives US\$400K Phase 1 Milestone Payment from Hologic**

**MELBOURNE, Australia (19 Jun 2024)** – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care (POC) diagnostic technologies, has today received a US\$0.4 million payment from Hologic for completion of the Phase 1 milestone under the Hologic Development Agreement, announced on 11 January 2024.

On 6 May 2024, Lumos announced it had achieved completion of milestones relating to Phase 1 under the Development Agreement. This revenue will be recognized in the current financial year, FY2024, with US\$0.2 million recognized in Q3 and the remaining US\$0.2 million booked into Q4.

Lumos CEO and Managing Director, Doug Ward commented, *“We were happy to report completion of this milestone in May, highlighting that all was moving in the right direction under this important agreement with Hologic. The associated payment further strengthens our cash position.”*

The Hologic Development Agreement is a three-phase program with a total value of US\$4.7 million. Phase 2 of the Development Agreement has commenced and is designed to demonstrate that the assay can detect the biomarkers associated with the next generation fFN test. Successful completion of Phase 2 will trigger a US\$0.6 million milestone payment. The balance of the Development Agreement, of US\$3.7 million, is payable following the successful completion of the Phase 3 milestones.

**-Ends-**

***This announcement has been approved by the Lumos Disclosure Committee.***

## **About Lumos Diagnostics**

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com).

## **Forward-Looking Statements**

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

### **Media Contact:**

Haley Chartres – Australia  
H<sup>^</sup>CK Director  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 (0) 423 139 163

### **Investor Contact:**

Jane Lowe  
Managing Director, IR Department  
[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)  
+61 411 117 774

### **Company Registered Office:**

Lumos Diagnostics Holdings Ltd  
Level 4, 100 Albert Rd  
South Melbourne, VIC 3205, Australia  
+61 3 9087 1598